home / stock / aqst / aqst news


AQST News and Press, Aquestive Therapeutics Inc. From 02/22/23

Stock Information

Company Name: Aquestive Therapeutics Inc.
Stock Symbol: AQST
Market: NASDAQ
Website: aquestive.com

Menu

AQST AQST Quote AQST Short AQST News AQST Articles AQST Message Board
Get AQST Alerts

News, Short Squeeze, Breakout and More Instantly...

AQST - Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET

WARREN, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative produc...

AQST - Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

WARREN, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative product...

AQST - Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives

Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of 2023 Anticipates receipt in the coming months of FDA response to request for Libervant ™ (diazepam) Buccal Film accelerated market access Expects preli...

AQST - Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

FDA continues to indicate that the Company can conduct a comparability study rather than efficacy studies FDA provides clear guidance on approvability expectations for pharmacokinetic (PK) performance and patient administration attributes Company continues to anticipate a potentia...

AQST - Assertio Holdings: Acquiring Good Products Is The Key To Success

Summary Assertio Holdings is a pharmaceutical company based on a niche model that is focused on digital, non-personal promotion. Last Q3 showed great revenue and cash flow growth. The company's growth strategy is based on market acquisitions. The share price valuation seems to b...

AQST - Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

WARREN, N.J., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today the publication of a crossover food effe...

AQST - Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WARREN, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today that the management team will participat...

AQST - Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting

WARREN, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, will present three abstracts recapping positive data fro...

AQST - My Top 5 U.S. Stocks Under $10

Summary After a rough September, we’re approaching the season historically known for stronger performance. Although small-cap stocks can be more volatile than large-caps, cheap stocks often have high return potential. Offering attractive valuations, above-average growth, an...

AQST - Aquestive Therapeutics, Inc. (AQST) Q3 2022 Earnings Call Transcript

Aquestive Therapeutics, Inc. (AQST) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Bennett Watson - Westwicke, Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, Chief Financial Officer ...

Previous 10 Next 10